Received Jun 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Late 2nd dose/ the 2nd dose was given at 6 months; This non-serious case was reported by a other health professional via sales rep and described the occurrence of drug dose administration interval too long in a patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received first dose on an unknown date). On an unknown date, the patient received the 2nd dose of Twinrix. On an unknown date, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose/ the 2nd dose was given at 6 months). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JUN-2025 On 02 June 2025, a GSK Sales Representative contacted Medical Information on behalf of a provider (Internal Medicine) with a query regarding the Twinrix vaccine. They had a question about the dosing and schedule of Twinrix, the normal schedule is 0, 1, 6 months. The patient got the 1st dose but then the 2nd dose was given at 6 months which led to , which led to lengthening of vaccination schedule. The reporter enquired if the patient needs one more dose and if so, when it should be administered. The Sales representative and HCP did not have any patient or product details.